Built on strength and resilience

To navigate an increasingly complex economic and competitive landscape, we sharpened our focus in 2024 to further enhance Octapharma’s resilience and to preserve the vitality of our business. Building on our proven business model and strengths, we launched our strategy to spur innovation and efficiency - providing us with a strong foundation for profitable growth. Our strategy’s aims are clear: securing our competitive position and long-term growth while fully leveraging the potential of our product portfolio and organisation.

In 2024, our continued focus on operational excellence, patient care, and responsible value creation has once again delivered strong and consistent growth in sales and profitability. Sales rose by 6.1% in the year to €3.466 billion, while operating income was €532 million. We are confident that we will further increase net sales and operating income in 2025.

As you will see in this year’s report, we have advanced initiatives that both reinforce our position as a global leader in plasma proteins, and also help us meet the growing global demand for our products. These initiatives range from AI projects aimed at driving operational excellence, advancements in R&D and a strengthened and broadened approach to sustainability, through the appointment as the sole fractionator for the UK's plasma for medicines programme. Additionally, Magda from Croatia and Chen from Taiwan share their inspiring stories of overcoming life-changing conditions. These stories remind us of the human impact of the health solutions we work tirelessly to provide for patients all around the world.

During 2024, regulatory inspections by the US Food and Drug Administration (FDA) were successfully concluded at our Springe and Dessau sites in Germany. This - alongside the positive outcomes of national inspections in Stockholm and Vienna in the previous year - demonstrate that our manufacturing plants continue to meet the highest quality standards.

Our dedication to accessibility - a core component of our strategy - remains stronger than ever. In 2024, we continued to advance efforts to make our therapies more accessible to those in need. One example is the approval of our human coagulation factor VIII in China - which brings another important treatment option to hemophilia A patients.

Our growth plans in the US gained added momentum with key FDA approvals in our critical care portfolio. We received a label extension for our human fibrinogen concentrate to treat acquired fibrinogen deficiencies (AFD) and an Emergency Use Authorization (EUA) for lyophilised S/D treated plasma for military use. The successful completion of the LEX-211 (FARES-II) study, has established our four-factor prothrombin complex concentrate (PCC) as a first-line alternative to fresh frozen plasma (FFP) to manage bleeding in patients undergoing cardiac surgery.

We have stepped up our efficiency programmes across the organisation - including at our manufacturing sites. Alongside our various immunoglobulin (IgG) yield initiatives, these efficiency programmes form an important element in our strategic roadmap. At the same time, our Octapharma Plasma team has introduced a new streamlined operating model throughout our fleet of more than 180 plasma donation centres in the USA.

The past year has shown the strength of our company, and confirmed that we are well placed for sustainable long-term growth. None of this would have been possible without the hard work and commitment of our 11,141 employees, and the trust that healthcare professionals around the world place in us. We would like to thank our teams and all of you who have made our success possible. Looking ahead, we will build on this momentum and remain dedicated to innovation and excellence while creating responsible value for patients, society, and our employees - guided all along by our vision to advance human life.

Wolfgang Marguerre
Chaiman and CEO, Octapharma Group

Tobias Marguerre
Deputy Chaiman, Octapharma Group